共 92 条
[1]
Landen CN(2008)Early events in the pathogenesis of epithelial ovarian cancer J Clin Oncol. 26 995-1005
[2]
Birrer MJ(2004)Focus on epithelial ovarian cancer Cancer Cell. 5 19-24
[3]
Sood AK(2006)Systemic therapy for ovarian cancer: current status and new treatments Semin Oncol. 33 S3-11
[4]
Ozols RF(2005)Emerging drugs for ovarian cancer Expert Opin Emerg Drugs. 10 413-42
[5]
Bookman MA(1998)Chemotherapy resistance in ovarian cancer: new molecular perspectives Obstet Gynecol. 91 783-92
[6]
Connolly DC(2001)Up-regulation of transporters of the MRP family by drugs and toxins Toxicol Lett. 120 51-7
[7]
Daly MB(2005)ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines Mol Cancer. 4 18-24
[8]
Godwin AK(2005)Patterns of p53 mutations separate ovarian serous borderline tumors and low-and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation Am J Surg Pathol. 29 218-40
[9]
Schilder RJ(2000)BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma Br J Cancer. 82 436-91
[10]
Ozols RF(2001)Differential Expression of Apoptosis-Associated Genes bax and bcl-2 in Ovarian Cancer Methods Mol Med. 39 687-43